Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Xuemei Liao, Hui Ye & Tianmei Si. (2021) A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities. Neuropsychiatric Disease and Treatment 17, pages 453-469.
Read now
Read now
P. Chue, A. Malla, R.-H. Bouchard, S. Lessard, S. Ganesan, E. Stip, S. Johnson, E. Chen, Y.M. Ahn, Y.S. Kim, G. Robinson, C. Schweikert, A. Gendron & H. Eriksson. (2013) The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia. Current Medical Research and Opinion 29:3, pages 227-239.
Read now
Read now
Wenyu Ye, Haya Ascher-Svanum, Yuka Tanji, Jennifer A Flynn & Michihiro Takahashi. (2011) Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan. Patient Preference and Adherence 5, pages 611-617.
Read now
Read now
Articles from other publishers (18)
Luis Agüera-Ortiz, Ganesh M. Babulal, Marie-Andrée Bruneau, Byron Creese, Fabrizia D’Antonio, Corinne E. Fischer, Jennifer R. Gatchel, Zahinoor Ismail, Sanjeev Kumar, William J. McGeown, Moyra E. Mortby, Nicolas A. Nuñez, Fabricio F. de Oliveira, Arturo X. Pereiro, Ramit Ravona-Springer, Hillary J. Rouse, Huali Wang & Krista L. Lanctôt. (2022) Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. Journal of Alzheimer's Disease 88:4, pages 1203-1228.
Crossref
Crossref
Giovanni Ostuzzi, Federico Bertolini, Federico Tedeschi, Giovanni Vita, Paolo Brambilla, Lorenzo Fabro, Chiara Gastaldon, Davide Papola, Marianna Purgato, Guido Nosari, Cinzia Del Giovane, Christoph U. Correll & Corrado Barbui. (2022) Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants. World Psychiatry 21:2, pages 295-307.
Crossref
Crossref
. (2021) Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”. Neuropsychopharmacology Reports 41:3, pages 266-324.
Crossref
Crossref
Dan Siskind, Erin Gallagher, Karl Winckel, Samantha Hollingworth, Steve Kisely, Joseph Firth, Christoph U Correll & Wade Marteene. (2021) Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. Schizophrenia Bulletin 47:4, pages 948-958.
Crossref
Crossref
Pruntha Kanagasundaram, Jiwon Lee, Femin Prasad, Kenya A. Costa-Dookhan, Laurie Hamel, Madeleine Gordon, Gary Remington, Margaret K. Hahn & Sri Mahavir Agarwal. (2021) Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis. Frontiers in Psychiatry 12.
Crossref
Crossref
Agnes Tully, Siobhan Smyth, Yvonne Conway, John Geddes, Declan Devane, John P Kelly & Fionnuala Jordan. (2020) Interventions for the management of obesity in people with bipolar disorder. Cochrane Database of Systematic Reviews 2020:7.
Crossref
Crossref
Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, John M. Kane & Christoph U. Correll. (2019) Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons. World Psychiatry 18:2, pages 208-224.
Crossref
Crossref
Johanna Taylor, Brendon Stubbs, Catherine Hewitt, Ramzi A. Ajjan, Sarah L. Alderson, Simon Gilbody, Richard I. G. Holt, Prakash Hosali, Tom Hughes, Tarron Kayalackakom, Ian Kellar, Helen Lewis, Neda Mahmoodi, Kirstine McDermid, Robert D. Smith, Judy M. Wright & Najma Siddiqi. (2017) The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis. PLOS ONE 12:1, pages e0168549.
Crossref
Crossref
Davy Vancampfort, Richard I.G. Holt, Brendon Stubbs, Marc De Hert, Katherine Samaras & Alex J. Mitchell. 2016. Life-Threatening Effects of Antipsychotic Drugs. Life-Threatening Effects of Antipsychotic Drugs
255
278
.
Jeffrey T. Rado, Kathryn S. Keim & Sheila M. Dowd. (2013) Management of Antipsychotic-Induced Weight Gain. Psychopharm Review 48:7, pages 49-56.
Crossref
Crossref
Richard I. G. Holt & Robert C. Peveler. 2011. The Metabolic Syndrome. The Metabolic Syndrome
177
193
.
Miquel Bernardo, Eduard Vieta, Jerónimo Saiz Ruiz, Fernando Rico-Villademoros, Cecilio Álamo & Julio Bobes. (2011) Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. Revista de Psiquiatría y Salud Mental (English Edition) 4:3, pages 150-168.
Crossref
Crossref
Miquel Bernardo, Eduard Vieta, Jerónimo Saiz Ruiz, Fernando Rico-Villademoros, Cecilio Álamo & Julio Bobes. (2011) Recomendaciones para el cambio de antipsicóticos. Posicionamiento de la Sociedad Española de Psiquiatría y Sociedad Española de Psiquiatría Biológica. Revista de Psiquiatría y Salud Mental 4:3, pages 150-168.
Crossref
Crossref
Olawale OsuntokunBrian MillenWen I XuLudmilla A KryzhanovskayaCarol Robertson-PlouchJanice L CarlsonNayan AcharyaSara A Corya. (2010) Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. Journal of Psychopharmacology 25:5, pages 630-638.
Crossref
Crossref
Linda Björkhem-BergmanAnnika B AsplundJonatan D Lindh. (2010) Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. Journal of Psychopharmacology 25:3, pages 299-305.
Crossref
Crossref
Anitha Mukundan, Guy Faulkner, Tony Cohn & Gary Remington. (2010) Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database of Systematic Reviews.
Crossref
Crossref
J. Karagianis, J. Landry, V. P. Hoffmann, L. Grossman, L. De Haan, G. Maguire, R. Milev & S. Holt. (2010) An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study. International Journal of Clinical Practice 64:11, pages 1520-1529.
Crossref
Crossref
RIG Holt & RC Peveler. (2010) Diabetes and cardiovascular risk in severe mental illness: a missed opportunity and challenge for the future. Practical Diabetes International 27:2, pages 79-84ii.
Crossref
Crossref